TransMedics
26
4
9
14
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
7.7%
2 terminated/withdrawn out of 26 trials
87.5%
+1.0% vs industry average
0%
0 trials in Phase 3/4
71%
10 of 14 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (26)
Decreasing Edema With a Novel OCS Solution Trial
Role: lead
Enhancing Heart Allograft Function With the OCS Heart System Trial
Role: lead
OCS Heart Perfusion Post-Approval Registry
Role: lead
US National OCS Heart Perfusion (OHP) Registry
Role: lead
OCS DCD Heart + CAP Continued Follow-Up
Role: lead
OCS Liver DCD Trial
Role: lead
US National TOP Registry
Role: lead
OCS™ Lung TOP Registry For Donor Lungs for Transplantation
Role: lead
OCS Liver Perfusion (OLP) Post-Approval Registry
Role: lead
OCS Heart EXPAND + CAP Continued Follow-Up
Role: lead
Heart EXPAND Continued Access Protocol
Role: lead
International EXPAND Heart Pivotal Trial
Role: lead
US National OCS Liver Perfusion (OLP) Registry
Role: lead
OCS Liver PROTECT Continued Access Protocol
Role: lead
Donor After Circulatory Death Heart CAP Trial
Role: lead
Donors After Circulatory Death Heart Trial
Role: lead
OCS Lung System EXPAND II Trial
Role: lead
OCS Liver PROTECT Continuation Post-Approval Study
Role: lead
OCS Liver PROTECT Continued Access Protocol (CAP) Continuation Post-Approval Study
Role: lead
OCS Liver PROTECT Trial: Preserving and Assessing Donor Livers for Transplantation
Role: lead